Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: A review and suggested reporting framework

Applied Health Economics and Health Policy

Volumn 11, Issue 2, 2013, Pages 85-93

  Haji Ali Afzali, Hossein ^a   Gray, Jodi ^a   Karnon, Jonathan ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CALIBRATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHECKLIST; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL FEATURE; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; CROSS MODEL VALIDITY; ECONOMIC EVALUATION; EXTERNAL VALIDITY; FACE VALIDITY; HEART INFARCTION; HUMAN; INTERNAL VALIDITY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LIFE EXPECTANCY; MEDICAL DOCUMENTATION; MEDLINE; PRACTICE GUIDELINE; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; REIMBURSEMENT; REVIEW; VALIDITY;

BENCHMARKING; CALIBRATION; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; EMPLOYEE PERFORMANCE APPRAISAL; HUMANS; MODELS, ORGANIZATIONAL; PRACTICE GUIDELINES AS TOPIC;

EID: 84877076190     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0012-6     Document Type: Review

References (50)

1. Hall PS, McCabe C, Brown JM, et al. Health economics in drug development: efficient research to inform health care funding decisions. Eur J Cancer Care. 2010;46:2674-80.
2. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci. 1998;1:133-40.
3. Buxton MJ, Drummond MF, Van Hout BA, et al. Modeling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217-27.
4. Karnon JE, Goyder E, Tappenden P, et al. A review and critique of modelling in prioritising and designing screening programs. Health Technol Assess. 2007;11:1-145.
5. The ISPOR-SMDM Joint Modeling Good Research Practices Task Force [online]. Available from URL: http://www.ispor.org/taskforces/GRPModelingTf.asp [Accessed 2012 March 26].
6. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics. 2000;17:461-77.
7. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1-158.
8. McCabe C, Dixon S. Testing the validity of cost-effectiveness model. Pharmacoeconomics. 2000;17:501-13.
9. Haji Ali Afzali H, Karnon J, Gray J. A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources. Pharmacoeconomics. 2012;30:461-82.
10. Tarride J, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010;28:255-77.
11. Sendi PP, Craig BA, Pfluger D, et al. Systematic validation of disease models for pharmacoeconomic evaluations. J Eval Clin Pract. 1999;5:283-95.
12. Dams J, Bornschein B, Reese JP, et al. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review. Pharmacoeconomics. 2011;29:1025-49.
13. Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30:551-64.
14. Ferdinands JM, Mannino DM. Obstructive lung disease models: what is valid? COPD. 2008;5:382-93.
15. Stout NK, Knudsen AB, Kong CY, et al. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27:533-45.
16. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modelling good research practices Task Force. Med Decis Making. 2012;32:733-43.
17. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modelling studies. Value Health. 2003;6:9-17.
18. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19:43-55.
19. The Mount Hood 4 Modelling Group. Computer modelling of diabetes and its complications: a report on the fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638-46.
20. Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in health care. New York: Oxford University Press; 2011.
21. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:1043-53.
22. Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria. Pharmacoeconomics. 2011;29:51-62.
23. Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharamacoeconomics. 2011;29:35-49.
24. Grover SA, Coupal L, Lowensteyn I. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model. Am J Cardiovasc Drugs. 2007;7:441-8.
25. Logman JF, Heeg BM, Herlitz J, van Hout BA. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. Appl Health Econ Health Policy. 2010;8:251-65.
26. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil. 2000;20:147-55.
27. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800-6.
28. Latour-Perez J, de-Miguel-Balsa E. Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome. Pharmacoeconomics. 2009;27:585-95.
29. Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin. 2008;24:267-74.
30. Maniadakis N, Kaitelidou D, Siskou O, et al. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005;46:212-21.
31. Latour-Pérez J, Navarro-Ruiz A, Ridao-López M, et al. Using clopidogrel in non-ST segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health. 2004;7:52-60.
32. Yock CA, Boothroyd DB, Owens DK, et al. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med. 2003;115:382-9.
33. Heeg B, Peters R, Botteman M, et al. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics. 2007;25:769-82.
34. Latour-Pérez J, Balsa EM, Betegob L, et al. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health. 2008;11:853-61.
35. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. J Am Med Rec Assoc. 2000;6:2748-54.
36. Ward MJ, Eckman MH, Schauer DP, et al. Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain. Acad Emerg Med. 2011;18:279-86.
37. Menown I, Montalescot G, Pal N, et al. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. Adv Ther. 2010;27:181-91.
38. Schwenkglenks M, Brazier JE, Szucs TD, Fox KA. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011;14:24-33.
39. Priest VL, Scuffham PA, Hachamovitch R, et al. Cost-effectiveness of coronary computed tomography and cardiac stress imaging in the emergency department: a decision analytic model comparing diagnostic strategies for chest pain in patients at low risk of acute coronary syndromes. JACC Cardiovasc Imaging. 2011;4:549-56.
40. Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ. 2005;6:354-62.
41. Hirsch G, Homer J, Evans E, Zielinski A. A system dynamics model for planning cardiovascular disease interventions. Am J Public Health. 2010;100:616-22.
42. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132:780-7.
43. Bravo Vergel Y, Palmer S, Asseburg C, et al. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart. 2007;93:1238-43.
44. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada [online]. Available from URL: http://inahta.episerverhotell.net/upload/HTA-resources/AboutHTA-Guidelines-for- the-Economic-Evaluation-of-Health-Technologies.pdf [Accessed 2012 Sep 26].
45. Checklist for authors of modelling studies submitted to Pharmacoeconomics [online]. Available from URL: http://adisonline.com/pharmacoeconomics/ documents/PEC-modellingchecklist.pdf [Accessed 2012 Sep 26].
46. Scottish Medicines Consortium. Guidance to manufacturers for completion of new product assessment form (NPAF) [online]. Available from URL: www.scottishmedicines.org.uk [Accessed 2012 Jul 27].
47. Haji Ali Afzali H, Karnon J. Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models. Pharmacoeconomics. 2011;29:823-5.
48. Haji Ali Afzali H, Karnon J, Merlin T. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making. doi: 10.1177/0272989X12458160.
49. Kopec JA, Finès P, Manuel DG, et al. Validation of population-based disease simulation models: a review of concepts and methods. BMC Public Health. 2010;10:710.
50. McCabe C, Chilcott J, Claxton C, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ. 2010;340:1285-8.